Identification of an Immune-related Six-long Noncoding RNA Signature As a Novel Prognosis Biomarker for Adenocarcinoma of Lung

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2020 Dec 16

PMID 33324975

Citations 12

Authors

Huikai Miao

Dongni Chen

Rongzhen Li

Jia Hu

Youfang Chen

Chunmei Xu

Zhesheng Wen

Affiliations

Soon will be listed here.

Abstract

Background: Lung adenocarcinoma (LUAD) is a heterogeneous disease with high mortality. Close attention has been paid to immunotherapy in LUAD treatment. However, immunotherapy has produced different therapeutic effects because of immune heterogeneity. Long noncoding RNAs (lncRNAs) are survival prognostic indicators with functions in the immune process. The present study was designed to examine the predictive power of immune-related lncRNAs in LUAD prognosis and investigated potential molecular mechanisms.

Methods: Transcriptome profiling and LUAD sample clinical information were retrieved from online database. The immune-related lncRNAs signature was identified by Cox regression. Survival analysis was used to verify the validity of the prognosis model. Then, possible biological functions were predicted and the abundance of infiltrating immune cells in LUAD samples were further analyzed.

Results: An immune-associated lncRNAs signature was established by combining six lncRNAs. Patients with LUAD were stratified into high- and low-risk groups using the six lncRNAs signature. Patients in different risk levels had significantly different prognoses (P<0.001), and the immune-associated lncRNAs signature was identified as an independent prognostic factor for LUAD. The functions of the lncRNA signature were confirmed as ubiquitin mediated proteolysis and signal sequence binding. The lncRNA signature negatively correlates with B-cell immune infiltration.

Conclusion: A reliable immune-related lncRNAs prognosis model for LUAD was identified. lncRNAs played a vital role in the tumor immune process and were associated with the LUAD prognosis. Research of lncRNAs in B-cell immune infiltration could provide new insight into the immunotherapy of LUAD.

Citing Articles

LncRNA gene polymorphisms and their influence on lung cancer patients in the Chinese Han population.

Wu H, Xie Y, Li A, Liu X, Guo L, Wu F Noncoding RNA Res. 2024; 10:252-260.

PMID: 39611047 PMC: 11602538. DOI: 10.1016/j.ncrna.2024.10.008.

Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma.

Zeng Z, Liang Y, Shi J, Xiao L, Tang L, Guo Y Diagnostics (Basel). 2022; 12(11).

PMID: 36428951 PMC: 9689875. DOI: 10.3390/diagnostics12112891.

Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients.

Xue Q, Wang Y, Zheng Q, Chen L, Jin Y, Shen X Heliyon. 2022; 8(5):e09521.

PMID: 35663751 PMC: 9157204. DOI: 10.1016/j.heliyon.2022.e09521.

Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma.

Zhu J, Huang Q, Peng X, Luo C, Liu S, Liu Z Front Oncol. 2022; 12:799475.

PMID: 35433487 PMC: 9012103. DOI: 10.3389/fonc.2022.799475.

Yin Z, Zhou M, Liao T, Xu J, Fan J, Deng J Front Oncol. 2022; 11:673567.

PMID: 35083132 PMC: 8784752. DOI: 10.3389/fonc.2021.673567.

References

Jia Q, Wu W, Wang Y, Alexander P, Sun C, Gong Z . Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018; 9(1):5361. PMC: 6299138. DOI: 10.1038/s41467-018-07767-w. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Skoulidis F, Heymach J . Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019; 19(9):495-509. PMC: 7043073. DOI: 10.1038/s41568-019-0179-8. View

Bodogai M, Lee Chang C, Wejksza K, Lai J, Merino M, Wersto R . Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 2013; 73(7):2127-38. PMC: 3618504. DOI: 10.1158/0008-5472.CAN-12-4184. View

Wang S, Liu W, Ly D, Xu H, Qu L, Zhang L . Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2018; 16(1):6-18. PMC: 6318290. DOI: 10.1038/s41423-018-0027-x. View

Chang J, Lee Y, Huang R . The impact of the Cancer Genome Atlas on lung cancer. Transl Res. 2015; 166(6):568-85. PMC: 4656061. DOI: 10.1016/j.trsl.2015.08.001. View

Wilkinson K, Ventii K, Friedrich K, Mullally J . The ubiquitin signal: assembly, recognition and termination. Symposium on ubiquitin and signaling. EMBO Rep. 2005; 6(9):815-20. PMC: 1369170. DOI: 10.1038/sj.embor.7400506. View

Ben-Neriah Y, Karin M . Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011; 12(8):715-23. DOI: 10.1038/ni.2060. View

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

10.

Heward J, Lindsay M . Long non-coding RNAs in the regulation of the immune response. Trends Immunol. 2014; 35(9):408-19. PMC: 7106471. DOI: 10.1016/j.it.2014.07.005. View

11.

Popovic D, Vucic D, Dikic I . Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014; 20(11):1242-53. DOI: 10.1038/nm.3739. View

12.

Lan Y, Xiao X, He Z, Luo Y, Wu C, Li L . Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Res. 2018; 46(11):5809-5821. PMC: 6009600. DOI: 10.1093/nar/gky214. View

13.

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

14.

Ebner P, Versteeg G, Ikeda F . Ubiquitin enzymes in the regulation of immune responses. Crit Rev Biochem Mol Biol. 2017; 52(4):425-460. PMC: 5490640. DOI: 10.1080/10409238.2017.1325829. View

15.

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

16.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

17.

Stankovic B, Bjorhovde H, Skarshaug R, Aamodt H, Frafjord A, Muller E . Immune Cell Composition in Human Non-small Cell Lung Cancer. Front Immunol. 2019; 9:3101. PMC: 6367276. DOI: 10.3389/fimmu.2018.03101. View

18.

Atianand M, Caffrey D, Fitzgerald K . Immunobiology of Long Noncoding RNAs. Annu Rev Immunol. 2017; 35:177-198. PMC: 6449690. DOI: 10.1146/annurev-immunol-041015-055459. View

19.

Morris L, Chan T . Lung Cancer Evolution: What's Immunity Got to Do with It?. Cancer Cell. 2019; 35(5):711-713. DOI: 10.1016/j.ccell.2019.04.009. View

20.

Dong Z, Zhang C, Li Y, Su J, Xie Z, Liu S . Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. J Thorac Oncol. 2017; 13(1):85-96. DOI: 10.1016/j.jtho.2017.10.020. View